ClinicalTrials.gg
RecruitingNCT07494110AuroraUpdated Mar 27, 2026

Aurora: AI-Based Narrative Intervention to Support Emotional Well-Being in Clinical and Non-Clinical Populations

An interventional study of chatbot-mediated supportive care intervention in Institutionalization, Elderly and Mental Health, sponsored by Universitat Autonoma de Barcelona. Recruiting at 2 sites in Spain. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Universitat Autonoma de Barcelona · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 107 studies in Psychological Well-Being with a site in Spain — 36 open to participants now, 47 under way, none of them phase 3. Psychological Well-Being · Spain.

Planned enrollment
70th of 86
55 · median 127
Started
2026
with 15 others
No phase
85 of 107
29 open now
Primary completion
2026-04
later than 17 of 46 live
Registered
85th of 107
by date
Lead sponsor
3 of 107
Universitat Autonoma de Barcelona

Among the 107 studies in Psychological Well-Being with a site in Spain, this one is the 70th largest by planned enrollment of the 86 interventional ones that give a count, is one of 16 that started in 2026, is one of 85 with no phase, reaches primary completion later than 17 of the 46 other live ones, and was the 85th registered.

Psychological Well-Being

2,208 studies on the registry are indexed under Psychological Well-Being; 730 are open to participants now.

Browse Psychological Well-Being studies →

Open to participants now

36 of the 107 studies in Psychological Well-Being with a site in Spain are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 403 Psychological Well-Being studies recruiting now, 223 (55%) set no upper age limit and 155 (38%) stop at 75 or younger; 121 take children under 18; 206 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Psychological Well-Being with a site in Spain, or all of them as a file.
02

Study summary

Aurora is an interdisciplinary project evaluating a chatbot-mediated supportive care intervention designed to promote emotional expression, autobiographical meaning-making, identity processes, and emotional well-being through guided narrative reconstruction. The Aurora system provides a structured, person-centered storytelling process supported by generative AI and human facilitation. Under the supervision of a trained facilitator (licensed mental health professional), participants engage in guided reminiscence and storytelling sessions to co-create a personalized "life book." The chatbot is not a diagnostic or treatment tool; rather, it is intended to support emotional expression, narrative reconstruction, and recovery-oriented processes. The study includes three non-randomized arms implemented sequentially: (1) a single-session arm of healthy adults focused on acceptability, usability, and emotional safety; (2) a four-hour intervention arm of adults with DSM-5 diagnosed mental disorders in residential care; and (3) a four-hour intervention arm of healthy older adults aged 65 years and older. Quantitative outcomes assess affect, mental well-being, and recovery-related constructs. Additional measures include usability, satisfaction, and qualitative feedback. Ecological momentary assessment (EMA) is conducted in Arms 2 and 3.

Read the detailed description

Pre-human development (in silico; not part of the clinical trial):

Prior to human participation, the Aurora system underwent an in-silico preparatory phase focused on content coherence and emotional safety using synthetic user profiles. Simulated interactions were reviewed by licensed mental health professionals to identify potential safety concerns and inform iterative refinements of the supportive narrative process. This preparatory work did not involve human participants and is not part of the clinical trial.

Human participants (clinical trial):

The study uses a sequential, non-randomized, three-arm interventional design with a total anticipated sample of 55 participants.

Arm 1: Healthy adults (single-session arm; n=20) Following informed consent, participants complete a single guided interaction with Aurora to generate a brief personal narrative. Outcomes include pre-session expectations, pre-post session affect (I-PANAS-SF), perceived usefulness and user experience, usability (System Usability Scale, SUS), satisfaction, and qualitative feedback.

Arm 2: Adults with DSM-5 diagnosed mental disorder in residential care (4-hour intervention arm; n=15) Following informed consent, participants complete four guided sessions over two weeks (two sessions per week, 1 hour per session). Outcomes include pre-session expectations, pre-post session affect (I-PANAS-SF) for each session, perceived usefulness and user experience, usability (SUS), satisfaction, qualitative feedback, and pre-post intervention self-report measures of mental well-being and recovery-related constructs. Ecological momentary assessment (EMA) is conducted during the 1-week pre-intervention period, the 2-week intervention period, and the 1-week post-intervention follow-up period.

Arm 3: Healthy older adults (aged 65 years and older; 4-hour intervention arm; n=20) Following informed consent, participants complete two guided sessions over two weeks (one session per week, 2 hours per session). Outcomes include pre-session expectations, pre-post session affect (I-PANAS-SF) for each session, perceived usefulness and user experience, usability (SUS), satisfaction, qualitative feedback, and pre-post intervention self-report measures of mental well-being and recovery-related constructs. Ecological momentary assessment (EMA) is conducted during the 1-week pre-intervention period, the 2-week intervention period, and the 1-week post-intervention follow-up period.

Data security and compliance:

All interactions occur in a secure professional environment. Textual data are pseudonymized during transcription and fully anonymized at the end of the project. Optional audio recordings are stored on encrypted offline devices and deleted after integration into the participant's life book. The study complies with applicable data protection and regulatory frameworks, including GDPR (EU 2016/679), LOPDGDD 3/2018, the EU AI Act (2024/1689), and institutional ethics guidelines.

03

Conditions studied

  • Institutionalization
  • Elderly
  • Mental Health
  • Wellbeing
  • Aging

Keywords

  • artificial intelligence
  • digital mental health
  • human-computer interaction
  • recovery
  • identity
  • autobiographical narrative
  • life story
  • reminiscence
  • wellbeing
  • storytelling
  • residential care
  • older adults
  • chatbot intervention
  • mental health
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Arm 1: Healthy Adults (Single-Session Intervention)

Age 18 years or older at screening.

Sufficient ability to read and understand Spanish to follow study instructions and complete questionnaires.

Ability to engage in a brief guided interaction and complete self-report measures.

Able and willing to provide written .

---

Arm 2: Adults with Diagnosed Mental Disorder in Residential Care (4-hour Intervention)

Age 18 years or older at screening.

Currently residing in a participating long-term mental health residential care facility and expected to remain there for the duration of the intervention and post-assessment period.

Documented diagnosis of a mental disorder according to DSM-5 criteria, confirmed by the treating clinician.

Minimal clinical stability at baseline, defined as all of the following:

Clinically stable in the judgment of the treating clinician.

No requirement for acute psychiatric hospitalization or crisis intervention in the previous 4 weeks.

Clinical Global Impression - Improvement (CGI-I) score between 3 and 5 inclusive during the 4 weeks prior to enrollment, indicating relative clinical stability.

Sufficient ability to understand spoken and written Spanish to participate in study procedures.

Ability to engage in guided interaction and provide feedback.

Able and willing to provide informed consent; when applicable, provision of legal guardian consent plus participant assent.

Willingness to participate in all study procedures.

---

Arm 3: Healthy Older Adults (≥65 Years; 4-hour Intervention)

Age 65 years or older at screening.

No self-reported diagnosis of a serious mental disorder (for example, psychotic disorder or bipolar disorder).

Sufficient ability to read and understand Spanish to participate in study procedures.

Adequate cognitive and communication abilities to engage in guided interaction and complete questionnaires.

Able and willing to provide written informed consent.

---

Exclusion criteria

Exclusion Criteria

Arm 1: Healthy Adults

Current acute medical or psychiatric condition that would compromise safe participation or data validity.

Moderate or high acute suicide or self-harm risk at screening.

Significant cognitive, communication, or comprehension impairment that would interfere with participation.

Explicit refusal to participate.

---

Arm 2: Adults with Diagnosed Mental Disorder in Residential Care

Current acute psychiatric decompensation requiring crisis-level care.

Moderate or high acute suicide or self-harm risk at screening or baseline.

High risk of emotional harm from autobiographical life review, defined as treating clinician judgment that narrative or reminiscence work is due to one or more of the following:

Severe clinical destabilization within the past 3 months.

Trauma-related re-experiencing symptoms.

Marked dissociative symptoms.

Inability to provide , with no legal representative available when required, or lack of participant assent when applicable.

Significant cognitive, communication, or comprehension impairment without available supports.

Explicit refusal to participate.

Imminent discharge or transfer that would prevent completion of the intervention or post-assessment.

---

Arm 3: Healthy Older Adults

Self-reported diagnosis of a serious mental disorder (for example, psychotic disorder or bipolar disorder).

Moderate or high acute suicide or self-harm risk at screening.

Current acute medical or psychiatric condition that would compromise safe participation.

Significant cognitive, communication, or comprehension impairment that would interfere with participation.

Explicit refusal to participate.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    Single-session - Healthy adults

    Healthy adults complete one Aurora session (single exposure) for platform refinement and usability assessment.

    Behavioral: chatbot-mediated supportive care intervention

  • Experimental
    Four-hour program - Adults with DSM-5 diagnosed mental disorder in residential care

    Adults (aged ≥18 years) with a DSM-5 diagnosed mental disorder, residing in long-term mental health residential care facilities, complete a four-session guided narrative program over two weeks (two sessions per week, 1 hour per session) with facilitation by a licensed mental health professional.

    Behavioral: chatbot-mediated supportive care intervention

  • Experimental
    Four-hour program - Healthy older adults (≥65 years)

    Healthy older adults (aged ≥65 years), with no self-reported diagnosis of a serious mental disorder, complete a two-session guided narrative program over two weeks (one session per week, 2 hours per session) with facilitation by a licensed mental health professional.

    Behavioral: chatbot-mediated supportive care intervention

Interventions

  • Behavioralchatbot-mediated supportive care intervention

    Aurora is a guided narrative reconstruction chatbot combining structured storytelling and reminiscence with an AI-based conversational system and support from a trained facilitator. Participants co-create a personalized life narrative ("life book") with written content and optional audio contributions (with explicit consent). Sessions occur in a secure professional environment and are supervised by licensed mental health professionals to ensure emotional safety. Aurora is not a diagnostic tool and is intended to promote emotional expression, recovery-oriented processes, and emotional well-being. The intervention is delivered in structured guided sessions. Arm 1 receives a single-session version for refinement and usability assessment, whereas Arms 2 and 3 receive a 4-hour intervention delivered over two weeks. The total intervention dose is equivalent across Arms 2 and 3. Session structure differs to accommodate participant characteristics.

    Also known as: Aurora, Aurora AI-Assisted Narrative Reconstruction Chatbot

06

What researchers measure

Primary outcomes

  1. Positive Affect (I-PANAS-SF - Positive Affect subscale-pre-post session change)

    Positive affect will be assessed using the Positive Affect (PA) subscale of the International Positive and Negative Affect Schedule - Short Form (I-PANAS-SF). Participants will rate their affect "right now." The endpoint is the change in PA from immediately before to immediately after each session across all treatment arms. Higher scores indicate higher positive affect.

    Time frame: Change from immediately before to immediately after each session, up to 2 weeks.

  2. Negative Affect (I-PANAS-SF - Negative Affect subscale - pre-post session change)

    Negative affect will be assessed using the Negative Affect (NA) subscale of the International Positive and Negative Affect Schedule - Short Form (I-PANAS-SF). Participants will rate their affect "right now." The endpoint is the change in NA from immediately before to immediately after each session across all treatment arms. Higher scores indicate higher negative affect.

    Time frame: Change from immediately before to immediately after each session, up to 2 weeks.

Secondary outcomes

  1. Positive Affect (I-PANAS-SF - Positive Affect subscale - baseline to 1-week follow-up change)

    Positive affect will be assessed using the Positive Affect (PA) subscale of the I-PANAS-SF. Participants will rate their affect "over the past week." The endpoint is the change in PA from baseline to immediately post-intervention in Arms 2 and 3. Higher scores indicate higher positive affect.

    Time frame: Change from baseline at 1 week after end of intervention.

  2. Negative Affect (I-PANAS-SF - baseline to 1-week follow-up change)

    Negative affect will be assessed using the Negative Affect (NA) subscale of the I-PANAS-SF, adapted to assess affect over the past week. The endpoint is the change in NA from baseline (pre-intervention) to 1-week follow-up after completion of the intervention in Arms 2 and 3. Higher scores indicate higher negative affect.

    Time frame: Change from baseline at 1 week after end of intervention.

  3. Mental well-being (WEMWBS)

    Mental well-being will be assessed using the Warwick-Edinburgh Mental Well-being Scale (WEMWBS; total score). Higher scores indicate greater mental well-being. The endpoint is change from baseline at 1 week after end of intervention in Arms 2 and 3.

    Time frame: Change from baseline at 1 week after end of intervention.

  4. Recovery-related outcomes aligned with CHIME framework

    Recovery-related outcomes will be assessed using an ad hoc self-report measure aligned with the CHIME framework. The measure includes six constructs (3 items each): social connectedness, hope, self-concept clarity, valued living, general self-efficacy, and self-esteem. A total composite score will be computed. Higher scores indicate more favorable recovery-related outcomes. The endpoint is the change from baseline (pre-intervention) to 1-week follow-up after completion of the intervention in Arms 2 and 3.

    Time frame: Change from baseline at 1 week after end of intervention.

Other outcomes

  1. Usability (System Usability Scale, SUS)

    Usability will be assessed using the System Usability Scale (SUS). The SUS is a 10-item self-report measure of perceived usability. Total scores range from 0 to 100, with higher scores indicating better perceived usability. In Arm 1, the SUS will be administered immediately after the single session. In Arms 2 and 3, the SUS will be administered at follow-up, 1 week after the end of the intervention.

    Time frame: Immediately after session (Arm 1); 1 week after end of intervention (Arms 2 and 3)

  2. User experience and satisfaction

    User experience and satisfaction will be assessed using study-specific self-report items covering expectations, perceived usefulness, and satisfaction/opinion. In Arm 1, this measure will be administered immediately after the single session. In Arms 2 and 3, it will be administered at follow-up, 1 week after the end of the intervention.

    Time frame: Immediately after session (Arm 1); 1 week after end of intervention (Arms 2 and 3)

  3. Ecological Momentary Assessment (EMA)

    Ecological momentary assessment (EMA) will be conducted in Arms 2 and 3. Participants will complete brief assessments twice daily across three predefined periods: (1) a 1-week pre-intervention baseline period, (2) the 2-week intervention period, and (3) a 1-week post-intervention follow-up period. EMA will include brief momentary items assessing affect, valued action, self-efficacy/empowerment, connectedness/hope, and psychological flexibility, capturing real-time (momentary) experiences.

    Time frame: Twice daily from 1 week before intervention to 1 week after end of intervention.

07

Study locations

1 of 2 sites recruiting
  • Llar Residència Gràcia(Grup ATRA)
    Barcelona, Barcelona 08012, Spain
    Not yet recruiting
  • Department of Clinical and Health Psychology; Universitat Autònoma de Barcelona
    Cerdanyola del Vallès, Barcelona 08193, Spain
    Recruiting
    • Albert Feliu-Soler Associate Professor Serra Húnter Fellow, PhD · Contactalbert.feliu@uab.cat · +34 93 581 2778
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared due to the sensitive nature of the data, which include mental health information and autobiographical narrative content from a vulnerable population. Data use is restricted to the approved study objectives under the conditions of the ethics committee approval and applicable data protection regulations (GDPR).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Apr 2026, 1 month after the start.

Of 1,274 non-industry interventional studies with no phase under Psychological Well-Being, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 34. This study's planned 1 month is below that.

Counting every sponsor, half of 1,317 studies reached it within 16 months; a quarter within 7 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2025
First posted
Mar 27, 2026
StartActual
Feb 12, 2026
Primary completionEst.
Apr 1, 2026
CompletionEst.
Apr 1, 2026
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07494110
Lead sponsor
Universitat Autonoma de Barcelona
Collaborators
Grup ATRA, AGAUR, Institut Municipal de Persones amb Discapacitat, Parc Sanitari Sant Joan de Déu, Universitat Oberta de Catalunya
Responsible party
Albert Feliu Soler (Associate Professor - Serra Húnter Fellow, Universitat Autonoma de Barcelona) — Principal investigator
First posted
Mar 27, 2026
Start date
Feb 12, 2026
Primary completion
Apr 1, 2026 (estimated)
Completion
Apr 1, 2026 (estimated)
Last update
Mar 27, 2026

Study contacts

Albert Feliu-Soler Associate Professor Serra Húnter Fellow, PhD
Contact
albert.feliu@uab.cat
+34935812778
Jaime Navarrete Postdoctoral Researcher, PhD
Contact
jaime.navarrete@sjd.es
+34 936 615 208 ext. 12734

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion